Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

Slides:

Advertisements

Similar presentations

Pulmonary response in sarcoidosis

Advertisements

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Longitudinal change in FVC, DLCO and RBC:TP.

Longitudinal imaging after initial diagnosis

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation Nicholas J. Gross, MD,

Flow diagram of the systematic research method for detecting matching microRNAs (miRNAs) in systemic sclerosis (SSc) and idiopathic pulmonary fibrosis.

ECG: electrocardiogram; PFT: pulmonary function testing; Dlco: diffusion capacity of the lung for carbon monoxide; BGA: blood gas analysis; HRCT: high-resolution.

High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

Radiology assessment of pulmonary amyloidosis

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Schematic representation of breathing levels during positive expiratory pressure in an obstructed patient. Schematic representation of breathing levels.

Changes of a) spirometric, plethysmographic, and b) impedance data at 5 Hz induced by bronchodilator in flow limited (□) and nonflow limited (▓) patients.

Sporadic Obliterative Bronchiolitis: Case Series and Systematic Review of the Literature Sean J. Callahan, MD, Andrew Vranic, MD, Lucia Flors, MD, Michael.

REVEAL pulmonary arterial hypertension (PAH) risk score.

a) Chest radiograph showing bilateral coarse interstitial shadowing

Impact of immunosuppressive therapy on pulmonary function, recurrence of diffuse alveolar haemorrhage (DAH) and chest computed tomography (CT) findings.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Changes in operating lung volumes are shown as ventilation increases with exercise in a) age-matched normal subjects (n = 25) and b) chronic obstructive.

Schematic representation of the current evidence for the association of cadmium exposure with smoking-related lung disease including chronic obstructive.

Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.

تست عملکرد ریوی SPIROMETERY.

Patient case study 2—fibrotic uILD in the setting of IPAF

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

Forest plots of the correlation between high-resolution computed tomography (HRCT) scores and pulmonary function test values. Forest plots of the correlation.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.

Simplified diagram of the multidisciplinary process to diagnose interstitial lung disease, including a clinician, radiologist, pathologist and also a geneticist:

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Morphological subtypes of cyst-related primary lung malignancies

Algorithm for the assessment of fitness to fly in chronic obstructive pulmonary disease patients. Algorithm for the assessment of fitness to fly in chronic.

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Effects of N-acetylcysteine (▒) and placebo (░) on vital capacity (VC) and diffusing capacity of the lung for carbon monoxide (DL,CO) depending on baseline.

This schematic view of the morpho-functional unit of the lung (alveolus) depicts the main differences in cellular composition in idiopathic pulmonary fibrosis.

Change in physiological variables from baseline values a) at rest and b) during exercise after saline infusion and exposition to different β-blocker agents.

Pathophysiology of obesity hypoventilation syndrome (OHS).

A) Small pulmonary arteries within a fibrotic area (usual interstitial pneumonia lung). a) Small pulmonary arteries within a fibrotic area (usual interstitial.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

Proportion of participants with access to a, b) a radiologist and c, d) a pathologist experienced in interstitial lung diseases to discuss cases of suspected.

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

A) Tidal volume (VT) (presented as % predicted of vital capacity (VC)), b) breathing frequency (Fb), c) dynamic inspiratory capacity (IC) and d) inspiratory.

Schematic diagram of the shared subgroups between asthma and chronic obstructive pulmonary disease (COPD). Schematic diagram of the shared subgroups between.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Distribution of diffusing capacity of the lung for carbon monoxide (DLCO) among 243 scleroderma patients who underwent right heart catheterisation (RHC)

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Distribution and change of the underlying disease in patients discharged with home mechanical ventilation (n = 854). ♦: chronic obstructive pulmonary disease;

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Is pulmonary function damaged by neoadjuvant lung cancer therapy

Endobronchial valve (EBV) treatment for emphysema, summary of treatment selection and outcome. Endobronchial valve (EBV) treatment for emphysema, summary.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

A) Dyspnoea response at rest, iso-time, and peak exercise in 20 patients with fibrotic interstitial lung disease during constant work-rate cycle exercise.

High-resolution computed tomography images of smoking-related interstitial lung diseases (ILDs). a) Pulmonary Langerhans cell histiocytosis, b) respiratory.

Schematic diagram of the DETECT study [56].

A) Smokers’ macrophages show a fine, golden haemosiderin cytoplasmic pigment; b) in respiratory bronchiolitis (RB), smokers’ macrophages are located in.

Tracing of tidal breathing followed by an inspiratory manoeuvre to total lung capacity (TLC) to record inspiratory capacity (IC), followed by a full expiration.

Interrelationships are shown between exertional dyspnoea intensity and a) minute ventilation (V′E) and b) the tidal volume (VT)/inspiratory capacity (IC)

Comparison of total lung capacity (TLC), slow vital capacity (SVC) and carbon monoxide transfer factor (Tlco) in patients with stable interstitial lung.

Presentation transcript:

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial lung disease progression. Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial lung disease progression. Four studies which used forced vital capacity (FVC) but which did not make a distinction between absolute and % predicted values were excluded from this figure. DLCO: diffusing capacity of the lung for carbon monoxide; VC: vital capacity; RV: residual volume. Melissa Caron et al. Eur Respir Rev 2018;27:170102 ©2018 by European Respiratory Society